|
|
<p>The national, multi-agency Medicines Repurposing Programme is hosted and funded by NHS England and is overseen by a steering group, including decision-making members from the Department, the Medicines and Healthcare products Regulatory Agency, the National Institute for Health and Care Excellence, the National Institute for Health and Care Research, and NHS England. Each of the national agencies brings a different contribution to the programme, in line with their respective regulatory and statutory responsibilities.</p><p>The programme steering group has not discussed adopting abiraterone for high-risk, non-metastatic hormone sensitive prostate cancer into the repurposing programme. This is because an off-label clinical commissioning policy covering the off-label use of abiraterone in this indication is being developed by NHS England and, in this case, NHS England considers this to be the most appropriate route to support a decision on routine patient access in the National Health Service. The policy is being considered through the established process in line with the current methods, which are available at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2016/12/Methods-National-clinical-policies-updated-July-2020-v2.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2016/12/Methods-National-clinical-policies-updated-July-2020-v2.pdf</a></p><p> </p> |